IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 30 March 2023 to 30 March 2023

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1] or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council [2])

(2023/C 116 I/01)

— **Issuing of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
30.3.2023	BIMERVAX	COVID-19 Vaccine (recombinant, adjuvanted)	Hipra Human Health, S.L.U. Avda. la Selva, 135, 17170 Amer (Girona), España	EU/1/22/1709	Emulsion for injection	J07BN	30.3.2023

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
NETHERLANDS

[1] OJ L 136, 30.4.2004, p. 1.
[2] OJ L 4, 7.1.2019, p. 43.